Validation of Strasbourg Environmental Exposure Chamber ALYATEC in Mite Allergic Subjects With Asthma

Inclusion criteria

• Subjects having signed the informed consent
• Subjects affiliated to a social security scheme
• Positive metacholine test
• FEV1 value > 70% of theoretical FEV1 value
• Asthma Control Test (ACT) ≥ 20/25 in 4 weeks prior to EEC exposure

Group A:

• Mild allergic asthma to HDM (GINA 1 or 2) with associated rhinitis and/or conjunctivitis.
• Positive skin prick-test to Dpt and Df (wheal diameter >5 mm compared to the negative control)
• Specific immunoglobulin E (IgE) for Dpt and Df > 0.7 kU/L

Group B:

• Mild allergic asthma (GINA 1 or 2) not sensitized to HDM with associated rhinitis and/or conjunctivitis.
• Negative skin prick-test and specific IgE for Dpt and Df.
• Positive skin prick-test and specific IgE for another allergen.

Exclusion criteria

• Uncontrolled asthma
• Asthma Control Test (ACT) < 20/25 in 4 weeks prior to EEC exposure
• Use of oral corticosteroids in the 4 weeks preceding inclusion in the study
• Use of biotherapy in the 4 months preceding inclusion in the study
• Existence of a severe obstructive syndrome with FEV1 <70% of the theoretical value
• Obstruction triggered by spirometric evaluations
• Hospitalization for asthma or exacerbation in the last 4 weeks
• History of Acute Severe Asthma requiring hospitalization in intensive care or intubation
• Desensitization to dust mite allergens in the last 5 years
• Sensitization to allergens in the indoor environment (cat allergens or molds) with obvious exposure to these allergens
• Active tobacco: plus 10 cigarettes / day and tobacco history of +10 PA
• Uncontrolled systemic arterial hypertension
• Recent myocardial infarction (<3 months)
• Recent stroke (<3 months)
• Known arterial aneurysm
• Epilepsy under treatment
• Progressive tumor pathology
• Chronic renal pathology
• Hypersensitivity to one of the excipients used
• Subjects who participated in another clinical study in the three months prior to inclusion